Biotech Values

[flatlander_60048]

At first glance they seem similar to the results from Gylenia. However, I believe that Marth made comments that Gylenia was not a good drug due to side effects. I thought he had alluded that Laquinimod would have a much cleaner SE profile. The elevated liver enzymes may be a problem when long term usage are considered. The fact these elevated enzyme levels were noted to be reversible suggest that they reversed when treatment with Laquinimod was suspended. Did any of the discontinuations occur as a result of abnormal enzyme levels?

In any case, Teva is under pressure to show that they have a blockbuster replacement for copaxone, so one has to take Marth's statements with a grain of salt (especially when they are made before clinical testing has been fully completed).

FL